New Mpox Strain England – UKHSA Confirms First Recombinant Case

In December 2025, the UK Health Security Agency (UKHSA) announced it had identified a new recombinant mpox virus in a traveller who had recently returned to England from the Asia-Pacific region. The case represents the first known detection of this particular strain in the United Kingdom, and health authorities have since assessed the risk to the general population as low.

What is the new mpox strain detected in England?

The virus is a recombinant, meaning it contains genetic material from two distinct mpox clades: clade Ib and clade IIb. Neither UKHSA nor the World Health Organization has assigned it a specific name beyond describing it as a clade Ib/IIb recombinant. According to the UKHSA official announcement, the infection was identified through a vesicular swab taken from the traveller.

Key facts at a glance

• The new strain is a recombinant – it combines genetic material from two different mpox clades (Ib and IIb).
• Only one case has been reported in England so far, with no evidence of onward transmission.
• WHO and UKHSA are monitoring closely but have not raised the public health risk level.
• Mpox symptoms are similar to previous strains: rash, fever, swollen lymph nodes, muscle aches.
• Vaccines (JYNNEOS) are expected to be effective, but specific data on this recombinant strain is not yet available.

Core details about the strain

What are the symptoms of the new mpox strain?

The symptoms associated with this recombinant strain are consistent with those of mpox generally. UKHSA has advised people who have recently travelled to affected areas to seek medical help if they develop new spots, blisters, or ulcers within 21 days of returning. UKHSA travel guidance also recommends isolating at home and calling NHS 111 if such symptoms appear after travel.

How do symptoms compare to previous mpox strains?

Based on available data, the symptoms appear similar to those seen with earlier mpox lineages. These include fever, headache, muscle aches, swollen lymph nodes, and a characteristic rash that progresses through stages before crusting over. Health officials have not reported any unique or unusual clinical features specific to this recombinant strain.

How long after exposure do symptoms appear?

The incubation period for mpox typically ranges from 5 to 21 days. The UKHSA has advised anyone who develops a new rash, spots, or ulcers within three weeks of returning from an affected area to isolate and contact NHS 111. The World Health Organization has noted that conclusions about clinical characterization would be premature given the small number of confirmed cases.

How many mpox cases are there in the UK?

As of the latest updates, only one case of this recombinant strain has been confirmed in the United Kingdom. That case was detected in December 2025 by UKHSA. Health authorities followed up with close contacts and reported no further cases. The WHO global update issued in February 2026 confirmed that, at that time, no additional UK cases had emerged.

Was the patient a traveller?

Yes. UKHSA stated that the individual had recently travelled from a country in the Asia-Pacific region. The precise country has not been publicly identified, and the WHO noted that the infection may already involve transmission across multiple countries in three WHO regions, suggesting it could be more widespread than currently documented.

Are there other confirmed cases globally?

WHO has linked the recombinant to at least two confirmed cases in total: the UK case and a case in India that was later retrospectively reclassified as closely related. The agency has also emphasised that, given the small number of cases, any conclusions about transmissibility or clinical severity would be premature. Virological analysis of the UK case confirmed that repeat sequencing supported the virus being replication-competent.

Geographic context of the detection

The travel history points to South-East Asia or the broader Asia-Pacific region, depending on the source. WHO has described the region of travel as the Asia Pacific region, and this is the most authoritative account available.

How is the UK responding to the new mpox strain?

UKHSA acted quickly after the detection. The agency conducted contact tracing, followed up with close contacts, and performed genomic sequencing of the virus. No further cases were identified as a result of those efforts. UKHSA has stated that the risk to the UK population remains low.

What has UKHSA done so far?

Upon confirming the case, UKHSA notified international health authorities, published a public announcement, and updated its travel guidance. The agency has also made it clear that vaccination is not recommended for the majority of travellers and that the risk to most travellers is low. UKHSA’s ongoing surveillance includes monitoring for any new cases presenting with mpox symptoms after travel.

What does WHO say about the strain?

The WHO has described the strain as a recombinant with genomic elements of clades Ib and IIb and has said it requires close monitoring. The organisation assessed the public health risk for the general population as low, while noting that risk is moderate for men who have sex with men with new or multiple partners. CIDRAP reported that WHO also reiterated that conclusions about transmissibility or clinical characterisation would be premature given the small number of cases.

Should people be concerned?

UKHSA has been clear that the risk to the general public in the UK is low. Health officials emphasise that this is a single, contained case with no onward transmission detected. However, the detection is considered notable from a scientific perspective, as it demonstrates that mpox can recombine while circulating in human populations. Expert commentary has described the finding as concerning because it highlights ongoing viral evolution.

When was the new mpox strain first detected?

The sequence of events surrounding the detection of this strain has been documented by multiple health authorities. Below is a timeline based on official announcements and reliable reporting.

1. December 2025: UKHSA detects the first case of clade Ib/IIb recombinant mpox in a traveller in England.
2. 8 December 2025: BBC reports the detection, citing UK officials and providing initial details about the case.
3. 9 December 2025: The Pharmacist and other outlets publish further details, including clinical context and guidance from UKHSA.
4. 14 February 2026: WHO confirms a second case in India that is retrospectively reclassified as closely related, and provides a global update on the new strain.

No further UK cases have been reported as of February 2026. The timeline may be updated as more information becomes available from ongoing surveillance.

Is the new mpox strain dangerous?

Health authorities have distinguished between what is known with confidence and what remains uncertain about this recombinant strain. The table below separates established facts from areas where information is still incomplete.

What does the discovery of a recombinant mpox strain mean?

Mpox is endemic in parts of Africa and has two main clades: clade I, which is generally associated with more severe disease, and clade II, which is typically less severe. Clade Ib has been linked to a severe outbreak in the Democratic Republic of Congo during 2023–2024. The new recombinant strain, containing elements from both clade Ib and clade IIb, is notable because it demonstrates that mpox can recombine while circulating in human populations.

Recombinants are considered rare but possible in orthopoxviruses, and scientists have described this finding as a signal that ongoing global circulation of mpox allows the virus to evolve. Flu Diary noted that the detection underscores the importance of continued genomic surveillance. At the same time, experts have emphasised that this discovery does not prove the recombinant behaves more aggressively or spreads differently than other mpox lineages.

The case also highlights how global travel can introduce novel viral variants across borders. No community spread has been identified in the UK, and health authorities continue to monitor the situation closely.

What are the official sources and experts saying?

UKHSA and WHO have both issued statements about the case. Their assessments are based on available laboratory and epidemiological data, and they have been careful not to overstate what is currently known.

“The risk to the UK population remains low.”

— UK Health Security Agency

“This is a new recombinant mpox strain that requires close monitoring.”

— World Health Organization

Scientific commentary has further framed the finding as a reminder that mpox can evolve in ways that were not fully anticipated. The Science Media Centre collected reactions from researchers who noted that continued surveillance and genomic sequencing are essential tools for tracking the virus’s evolution.

What is the key takeaway for people in the UK?

The detection of this recombinant mpox strain in England is a single, contained case with no onward transmission identified. UKHSA and WHO both assess the risk to the general population as low. Anyone who develops a new rash, blisters, or ulcers within 21 days of travel from an affected region should isolate at home and call NHS 111. For broader guidance on viral infections that cause skin symptoms, you can read our Hand Foot and Mouth in Kids: Symptoms, Contagiousness, Treatment guide, which covers similar symptom patterns in a different context. If you are concerned about accessing medical care, our Find Nearest A&E: Access, Costs & When to Go (UK & Ireland) resource may also be useful.

Frequently asked questions